We are live on ! Find out more
IBBJ

Defiance Nasdaq Junior Biotechnology ETF
IBBJ

Delisted

IBBJ was delisted on the 2nd of December, 2021.

Back to rankings

2 hedge funds and large institutions have $52K invested in Defiance Nasdaq Junior Biotechnology ETF in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
2
Holders Change
+2
Holders Change %
–
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EIP
Ellis Investment Partners
Pennsylvania
+$27.9K
2
UBS Group
UBS Group
Switzerland
+$23.2K

Top Sellers

No sellers this quarter

IBBJ Hedge Fund Activity: Q3 2020 in Review

2 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Defiance Nasdaq Junior Biotechnology ETF (IBBJ) for Q3 2020, worth a combined $52K.

Buyers outnumbered sellers: 2 funds opened new IBBJ positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Ellis Investment Partners, opening a new position worth an estimated $27.9K.

  • 2 institutional investors held Defiance Nasdaq Junior Biotechnology ETF (IBBJ) as of Q3 2020, up from 0 in Q2 2020.
  • Funds reported $52K of Defiance Nasdaq Junior Biotechnology ETF stock for Q3 2020.
  • 2 funds opened new Defiance Nasdaq Junior Biotechnology ETF positions in Q3 2020 and 0 closed out, a net change of +2 holders.
  • The largest Defiance Nasdaq Junior Biotechnology ETF buyer in Q3 2020 was Ellis Investment Partners, an estimated $27.9K added.

Based on aggregated 13F filings for Q3 2020.